American Thoracic Society - Sanofi Investor Call

Annualized rate of moderate or severe COPD exacerbations ± 95% CI Primary Outcome: Annualized Rate of Exacerbations 1.2 1.0- T Hå 1.10 P<0.001 -30% 0.8 0.6 0.4- 0.2- T 0.78 Cumulative mean number of events ± 95% CI 1.07 0.9- Placebo Dupilumab 0.8 0.7- 0.6- 0.5- 0.4- 0.3- 0.2- 0.1- 0.0 0 4 8 12 16 20 24 28 32 36 40 44 48 52 Week 0 Placebo N=471 Dupilumab N=468 No. at Risk Placebo ATS 2023 471 470 466 461 457 457 456 451 451 449 445 442 441 437 Dupilumab 468 467 465 464 462 460 458 457 456 454 451 450 448 437 25

View entire presentation